US2003103935A1PendingUtilityA1

Soluble variants of type I membrane proteins, and methods of using them

54
Assignee: WISTAR INSTPriority: Oct 18, 1991Filed: Nov 19, 2002Published: Jun 5, 2003
Est. expiryOct 18, 2011(expired)· nominal 20-yr term from priority
Inventors:Alban J. LinnenbachHilary KoprowskiDorothee Herlyn
C07K 14/705
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention describes novel soluble variants of type I membrane protein GA733-2 and methods of making and using them. In addition, the present invention describes a method of converting type I membrane proteins into secretory proteins which may be used for active immunotherapy against carcinomas and as reagents in the detection of GA733-2 expression on tumor cells.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for treating a mammalian subject with a cancer comprising the step of administering to said subject a pharmaceutical composition comprising an amount of the truncated polypeptide GA733-2E SEQ ID NO: 2 effective to induce an antigen-specific humoral immune response in said subject.  
     
     
         2 . The method according to  claim 1 , wherein said cancer is selected from the group consisting of colorectal carcinoma, breast carcinoma and pancreatic carcinoma.  
     
     
         3 . The method according to  claim 1 , wherein said composition comprises an adjuvant.  
     
     
         4 . The method according to  claim 1 , wherein said composition comprises an immunomodulator.  
     
     
         5 . The method according to  claim 4 , wherein said immunomodulator is selected from the group consisting of a cytokine, an interleukin and an interferon.  
     
     
         6 . The method according to  claim 1 , wherein said composition comprises a carrier.  
     
     
         7 . A composition for active immunotherapy of a mammalian subject with a cancer comprising an amount of the truncated polypeptide GA733-2E SEQ ID NO: 2 effective to induce an antigen-specific humoral immune response in said subject.  
     
     
         8 . The composition according to  claim 7 , wherein said cancer is selected from the group consisting of colorectal carcinoma, breast carcinoma and pancreatic carcinoma.  
     
     
         9 . The composition according to  claim 7 , further comprising an adjuvant.  
     
     
         10 . The composition according to  claim 7 , further comprising an immunomodulator.  
     
     
         11 . The composition according to  claim 10 , wherein said immunomodulator is selected from the group consisting of a cytokine, an interleukin and an interferon.  
     
     
         12 . The composition according to  claim 7 , further comprising a carrier.

Join the waitlist — get patent alerts

Track US2003103935A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.